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Abstract: Asthma and chronic obstructive pulmonary disease (COPD) are common diseases
which cause patients and society considerable difficulties. These are costly diseases which cause
substantial morbidity and death. Health care policy makers have made improving outcomes in
asthma and COPD a priority. Application of guideline recommended approaches to asthma
and COPD care in the real-life setting has been emphasized but outcomes have not improved.
Failure to improve outcomes may not be because of inconsistent applications of guideline recommendations, but rather because there are difficulties implementing the Expert Panel Report III
(EPR 3) method for categorizing asthma severity and the Global Initiative for Obstructive
Lung Disease (GOLD) method for diagnosing COPD. As these serve as the foundation for
treatment recommendations for these diseases, alternative approaches should be considered for
categorizing asthma severity and identifying COPD patients. Claims-based algorithms provide
an intriguing option for identifying persistent asthma patients and symptomatic COPD patients
in administrative databases. These methods could be used as the basis for pragmatic research,
both retrospective and prospective, on assessing outcomes of guideline recommended treatment
approaches in asthma and COPD. Important questions urgently need to be answered about how
guideline recommended approaches regarding use of long-acting inhaled β-agonist/inhaled
corticosteroid (LABA/ICS) in asthma and long-acting inhaled anti-muscarinic agent (LAMA)
and LABA/ICS in COPD affect outcomes in real-life situations.
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Asthma affects more than 25 million Americans, about 10% of the childhood population
and 8% of adults.1 In the US more than 5% of adults have chronic obstructive pulmonary disease (COPD).2 About 12 million Americans have been diagnosed with
COPD3 and an additional 12 million Americans probably have undiagnosed COPD.
Both asthma and COPD generate huge direct and indirect health care costs.2,4 Although
the mortality rate associated with asthma is fortunately low,1 the death rate attributed
to COPD is high.5 These sobering statistics have led to concerted efforts by health
care policy makers to improve overall care for asthma and COPD. The most important
initiative intended to advance care in asthma and COPD has been the development of
formally structured clinical practice guidelines for aiding in the diagnosis and management of these diseases.2,6–8 Despite the widespread dissemination of clinical practice
guidelines for asthma and COPD, there has been little evidence of improved outcomes.
Population-based surveys have shown no change in the need for asthma-related acute
care interventions, such as emergency department visits and hospitalizations, over the
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past decade.9,10 Deaths due to COPD are increasing.5 Health
care policy makers have responded to these disappointing
findings by suggesting that health care practitioners might
not be adhering to treatment approaches recommended in
clinical practice guidelines (also known as “best practices”).
To more effectively align actual clinical practice with “best
practices”, there has been a call in the US for the Centers
for Medicare and Medicaid Services to develop performance
measures in COPD. This would be a first step towards developing financial incentives, such as pay-for-performance, to
reward health care providers (ie, those certified or licensed
to practice medicine) who provide care in accordance with
guidelines.11 Pay-for-performance metrics have already
been implemented as a method to improve quality of care
in asthma.12,13
Improving outcomes in asthma and COPD through
more consistent application of recommendations in clinical
practice guidelines, even through the use of financial incentives, rests on the critical assumption that following these
recommendations will improve outcomes. Unfortunately, the
available clinical research in asthma and COPD might not
generally apply to assessing outcomes in real-life because
this literature is heavily weighted toward either mechanistic
studies or clinical trials supporting pharmaceutical products.
Furthermore, more than 90% of asthma and COPD patients
probably would not qualify for inclusion in typical asthma and
COPD clinical trials.14,15 An alternative approach to addressing how recommendations in clinical practice guidelines
might affect outcomes in typical asthma and COPD patients
being managed in real-life would be to use pragmatic study
designs. Pragmatic trials evaluate how interventions directly
pertinent to patient care affect clinically relevant outcomes
in real-world practice. They use broad eligibility criteria to
ensure that patients entered into these trials reflect the full
spectrum of disease. Pragmatic study methods merge seamlessly into usual clinical care rather than becoming artificial
constructs. To best understand how pragmatic research can
be used to improve outcomes in these diseases, key aspects
of management recommendations in asthma and COPD
guidelines should be critically examined.

Asthma severity as the basis
for initiating pharmacotherapy
Guidelines for asthma care rely on accurately categorizing
severity prior to beginning treatment.6,7 In the stepped-care
approach to treating asthma, more aggressive treatments
are reserved for more severe disease to appropriately match
the risks from drug treatment with the potential benefits.
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Methods for categorizing asthma severity have evolved from
clinically intuitive approaches based on symptoms, shortacting inhaled β-agonist (SABA) use and lung function, as
in the Expert Panel Report II (EPR 2), to the more complex
approach oriented towards considering the domains of
impairment and risk in the Expert Panel Report III (EPR 3).6,16
There are difficulties, though, with relying on methods in the
EPR 2 and 3 for categorizing asthma severity.

Awareness and understanding
of guidelines
An unconsidered, but limiting, factor for categorizing
asthma severity is how well health care providers are aware
of and understand guideline methods. In the mid-to late
1990s, there was generally poor adherence of asthma treatment with earlier versions of guidelines, possibly because
health care providers were simply unaware of guideline
recommendations.17 Over time, though, health care providers reported basing their asthma management more
reliably on guideline recommendations.18 Although physicians might report that their care is adherent to guidelines,
three examples demonstrate that health care providers do
not understand guideline approaches to asthma severity
categorization. The EPR 2 and 3 guidelines recommend that
asthma severity categorization should only be applied to
patients not receiving long-term controllers (Figure 1), but
the Global Initiative for Asthma (GINA) guidelines point
out that asthma severity classification is “often erroneously
applied to patients already on treatment.”7 There are many
examples of publications presenting results of asthma severity categorization which have been incorrectly reported in
patients already on long-term controllers.19,20 Doerschug
et al developed a 31-question, multiple-choice test to assess
physician understanding of the EPR 2 recommendations
for asthma diagnosis and care.21 This test was administered
to asthma specialists, general internists, family physicians,
and house staff. Asthma specialists, as expected, scored
higher on this test than others. Overall, though, only about
60% of questions were answered correctly. Physicians had
particular difficulty answering questions related to severity
categorization, answering fewer than 50% of these correctly.
Baker et al presented eight case summaries based on actual
patients with childhood asthma to pediatric asthma specialists
and asked them to categorize asthma severity using the EPR
2 approach.22 Agreement on asthma severity categorization
for the 14 specialists who completed the survey questionnaire
was poor. The EPR 2, published in 1997, contains a simpler
approach to asthma severity categorization than the EPR 3.6,16
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Figure 1 The EPR 3 recommended approach to asthma severity categorization for asthma patients 12 years of age and older is complex.
Notes: Just below the title is the reminder, often not considered, that this severity categorization method should only be applied to patients not currently taking long-term
controllers. The categorization method includes two domains. The impairment domain includes five variables which are both subjective and objective. The risk domain
includes exacerbations. The worst ranking in any individual impairment and risk domain determines overall severity.6
Abbreviation: EPR 3, Expert Panel Report III.

Undoubtedly, if health care providers were questioned about
their understanding of asthma severity categorization using
the more complicated EPR 3 methods, the results would
have been worse.
Physician misunderstanding of the methods for asthma
severity categorization is apparent in real life situations.
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Physician assessment of asthma severity often disagrees
with categorization based on symptom reporting by patients
and frequently is incorrect when compared to guideline
methods. In a survey of 3468 asthma patients in a managed
care organization23 patient-reported asthma symptoms were
used to categorize their asthma severity using EPR 2 criteria.
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The patients’ primary care physicians were separately asked
to estimate asthma severity, also using EPR 2 criteria.
There was only 31% concordance between asthma severity categorization based on patient symptom reporting and
physician estimates. The discordance was greatest in patients
categorized by their physician as having mild disease. Over
80% of these patients had symptoms which should have
placed them in the moderate or severe category. Incorrect
categorization of asthma severity by physicians results in
inappropriate treatment. Wolfenden et al determined asthma
severity in 4005 asthma patients based on their symptoms.24
The patients’ physicians were also asked to categorize asthma
severity using a method similar to the EPR 2 approach.
Physicians both overestimated and underestimated asthma
severity. In the 1565 patients categorized as having moderate
asthma severity by their symptoms, most were categorized
incorrectly by their physicians; physicians categorized 112
(7.2%) as having severe asthma and 824 (52.7%) as mild.
Asthma treatment in these patients was based on the (often
incorrect) physician asthma severity estimate. Consequently,
patients were frequently over-treated and under-treated.
These findings again demonstrate practical limitations in
using the asthma severity categorization method proposed
in the EPR 2 and 3 in real-life situations.

and major basic protein, airway epithelial shedding, and
increased basement membrane thickness, was seen in the
patients with asthma in remission (Figure 2). Although it
is not clear that treatment of the airway inflammation in
these patients would have been clinically justified, these
studies show that patients with intermittent asthma, as
determined by clinical severity categorization methods,
may have airway inflammation.

Airway inflammation
The severity categorization methods in EPR 2 and 3 make
an important distinction between intermittent and persistent
asthma.6 Regular use of a controller is recommended only
in persistent asthma. The preferred controller for persistent
asthma is an inhaled corticosteroid (ICS) because this is
the most effective class of drugs for controlling the airway
inflammation typically found in asthma. The implication of this approach is that severity categorization will
identify patients with airway inflammation treatable with
an ICS. Vignola et al performed bronchoalveolar lavage
and bronchial biopsies on 12 normal subjects, 24 patients
with mild intermittent asthma, and 18 patients with persistent asthma.25 Evidence of airway inflammation, eg,
lavage fluid eosinophilia, airway epithelial shedding, and
increased basement membrane thickness, was found in
the patients with mild intermittent asthma. Van den Toorn
et al performed bronchial biopsies in 17 healthy control
subjects, 18 patients with a history of asthma but in complete clinical remission and on no asthma medications,
and 19 patients with active asthma.26 Surprisingly, airway
inflammation, eg, presence of epithelial and subepithelial inflammatory mediators such as tryptase, chymase
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Figure 2 (A) A normal bronchial biopsy from a patient without asthma compared
with (B) a bronchial biopsy specimen from a patient with a history of asthma but
in complete remission demonstrates epithelial shedding and extensive presence of
α-major basic protein.
Note: Both of these findings indicate active ongoing airway inflammation. Reprinted
with permission of the American Thoracic Society. Copyright © 2012 American
Thoracic Society. LM Van den Toorn, SE Overbeek, JC de Jongste, K Leman, HC
Hoogsteden, JB Prins/2001/Airway inflammation is present during clinical remission
of atopic asthma/American Journal of Respiratory Critical Care Medicine/164/2107–2103.
Official Journal of American Thoracic Society.26
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Impairment
There are five variables in the impairment domain of the EPR
3 asthma severity categorization method (Figure 1). These
variables include subjective, patient-reported symptoms and
objective lung function measures. The scaling of the subjective variables is of uncertain clinical relevance. For example,
a minor change in symptom frequency from symptoms two
or fewer times per week to more than two times per week is
the threshold differentiating intermittent from persistent. No
allowance is made for possible confounding factors when
assessing two of the subjective variables, daytime symptoms
and interference with normal activity. In patients who have
asthma and who are also obese, obesity has been recognized
to have an independent effect on symptoms relevant to asthma
control.27 Also unclear is how the weighting of a subjective
variable against an objective one was determined, eg, daily
symptoms are considered the equivalent of a forced expiratory
volume in 1 second (FEV1) of 60%–80% predicted.
There is little information available on the relative roles
the variables in the impairment domain play in ultimately categorizing asthma severity. In one of the few studies to address
this issue, Colice et al categorized asthma severity using EPR
2 methods in 744 asthma patients not on ICS controllers who
were about to enter clinical trials with a new pharmaceutical
product.28 They found that 68.3% were categorized as having
severe persistent asthma. Remarkably, they found that nocturnal symptoms were the most common determining factor
for overall asthma severity categorization. Lung function
determined final asthma severity categorization less often than
SABA use. There was poor agreement among the variables in
categorizing asthma severity for individual patients.

Impairment versus risk
The EPR 3 is a novel approach to asthma severity categorization because it includes two domains for assessment, impairment and risk for exacerbations. Although both domains
include highly relevant clinical information for health care
providers to consider in caring for asthma patients, it is not
clear how health care providers should weigh the impairment
and risk domains in deciding on categorization and ultimately
treatment. For instance, a long-acting inhaled β-agonist
(LABA) in combination with an ICS will improve variables
in the impairment domain faster than increasing the dose
of an ICS because of the acute bronchodilator effects of the
LABA.29 However, increasing the dose of an ICS might have a
greater long-term effect on reducing the risk of exacerbations
than adding a LABA to a lower dose of ICS.30 Health care
providers might choose a LABA/ICS specifically because
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they are more concerned about early symptom control than
preventing later exacerbations.31

Asthma control
The GINA guidelines suggest basing severity on the intensity of treatment required to obtain control as an alternative
approach to asthma severity categorization,7 but the variables
used to assess asthma control are similar to those used for
severity categorization. A more fundamental problem with
this approach though, is understanding how well determining therapy based on the symptom-based methods recommended in guidelines will affect outcomes. Although this
is the approach that clinicians use in practice for managing
asthma, clinical trials addressing this issue are limited.
A large, prospective, randomized, parallel group trial used
EPR 2-based guideline methods for determining asthma
control as an endpoint for adjusting pharmacotherapy over
time.32 This study was designed to compare the effects of two
pharmaceutical products and did not employ a non-guidelinebased method as a comparison arm.
Guideline-based methods for determining asthma control
have been compared against methods using measures of airway
inflammation in conjunction with symptoms in guiding treatment. Green et al tested an approach to asthma management
using eosinophilia in induced sputum together with a guideline
method for assessing asthma control against using guideline
methods only.33 Sont et al compared adding methacholine testing to determine bronchial hyperreactivity in conjunction with
a guideline method for determining asthma treatment to simply
relying on the guideline method.34 In both studies, adding a measure of airway inflammation resulted in significantly fewer exacerbations than simply relying on guideline methods (Figure 3).
These studies suggest that tailoring treatment to asthma control,
determined by guideline recommended methods, may not provide the best outcomes. However, the techniques used in those
studies are time consuming and require considerable technical
expertise to perform correctly. An easier to perform measure
of airway inflammation, monitoring exhaled nitric oxide
levels, has also been tested as a way to further improve asthma
management over using guideline methods alone, but has not
been shown to provide consistent benefit in either reducing
exacerbations or improving symptom control.35–37

Pragmatic research approaches
to identifying asthma patients
and categorizing severity
The current guideline-recommended approach to categorizing asthma severity is flawed. Health care providers are
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Figure 3 (A) Cumulative severe exacerbations were significantly reduced
when asthma treatment was determined by induced sputum eosinophilia used in
conjunction with guideline methods (sputum management group) than guideline
methods alone (BTS management group).33 (B) The cumulative incidence of mild
first exacerbations was significantly lower when asthma therapy was adjusted based
on methacholine testing used along with guideline methods (AHR-strategy) than
guideline methods alone (Reference-strategy).34
Note: 3B is reprinted from Lancet, Vol 360, Issue 9347, Ruth H Green, Christopher E
Brightling, Susan McKenna, Beverley Hargadon, Debbie Parker, Peter Bradding,
Andrew J Wardlaw, Ian D Pavord, Asthma exacerbations and sputum eosinophil
counts, Pages 1715–1721, Copyright 2002, with permission from Elsevier.
Abbreviations: AHR, airway hyperresponsiveness; BTS, British Thoracic Society.

aware of guidelines, but objective evidence indicates that
they do not understand how to use guideline recommended
methods to categorize asthma severity. In clinical practice,
inability to use guideline-recommended methods leads to
incorrect treatment. Furthermore, there are difficulties with
the structure of the guideline-recommended approach to
asthma severity categorization. The clinical relevance of
changes for some variables within the impairment domain
is not certain. Health care providers are not provided clear
guidance on how the impairment domain should be weighed
against the risk domain in making treatment decisions. Using
clinical measures of asthma control to guide treatment may
not provide optimal outcomes when compared to approaches
using markers of airway inflammation.
Pragmatic research may prove to be an important tool
to use in developing methods for categorizing asthma
severity which are accurate and easy to use for health care
providers. Any approach for asthma severity categorization
developed through pragmatic research should meet three
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criteria: it should be easily understandable for health care
providers, appropriate for use in patients who are either on
long-term controllers or only short-acting relievers, and
applicable in both the clinic setting for the individual patient
and the epidemiologic research arena for large populations.
One approach to asthma severity categorization which has
generated considerable interest is based on the Health Plan
Employer Data and Information Set (HEDIS). The HEDIS was
developed by the National Committee for Quality Assurance
as a way to assess health plan quality of care performance. Use
of the HEDIS approach for evaluating health care quality has
been widely accepted by health plans and employers, as well as
regulators, consumers, and public purchasers of health care.38
The HEDIS includes a component for identifying persistent
asthma. Patients with persistent asthma are defined in HEDIS
as those having four or more asthma medication dispensings, one or more acute inpatient or emergency department
discharge(s) with a primary diagnosis of asthma, or four or
more outpatient visits with asthma listed as one of the diagnoses, and two or more asthma medication dispensings.39
Initial work with the HEDIS method for identifying
persistent asthma identified several potential problems with
this approach. First, the HEDIS method misclassifies patients
with intermittent asthma as having persistent asthma.38–40
To address this problem, Colice et al modified the HEDIS
approach by adding another step which identifies persistent
asthma based on SABA and oral corticosteroid use over a
1-year period.41,42 This approach has been useful in evaluating
asthma costs in database analyses of large populations. As a
further modification to the HEDIS method, asthma severity
can be categorized into mild, moderate, and severe persistent
groups based on patient pharmacotherapy. Second, claimsbased algorithms for asthma severity have been criticized
because they do not incorporate physiologic measures of lung
function. Birnbaum et al have shown that adding spirometry
results to the HEDIS claims-based algorithm modified by
Colice et al did not appreciably affect asthma severity categorization.43 Third, because asthma is a variable disease over
time, patients with persistent asthma identified during 1 year
might not have persistent asthma the next year.44 Schatz and
Zeiger have suggested that applying the HEDIS method over
2 years, rather than one, will adequately address this issue.45
Other approaches to assessing asthma control and outcomes involve administrative database review of medication
use. Studies in health maintenance organizations have shown
that records of SABA dispensing can provide an insight into
risk for future acute asthma health care use, such as asthmarelated emergency department visits and hospitalizations.46,47
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The number of SABA canisters dispensed to a patient over
time has also been found to be a useful indicator of asthma
symptom control.47 An argument against relying on SABA
dispensing records obtained from claims databases has been
that some SABAs have been available over the counter, but
these products will soon be removed from the market.48 An
approach based on simply counting SABA dispensing has
been refined to include dispensing records for long-acting
controllers. If SABA use is considered along with controller
use, a ratio of medication dispensing for long-term controllers
and SABAs can be calculated. A ratio of at least 0.5, indicating that patients are preferentially filling their prescriptions
for long-term controllers rather than relying on SABA use to
relieve symptoms, has been associated with a lower likelihood
for asthma exacerbations.49–51
Schatz and Zeiger suggested that, combined with information obtained from administrative databases on SABA
and long-term controller use, and with results from asthma
control questionnaires administered by telephone, the HEDIS
method is a reasonable approach to evaluating quality of care
in asthma management in large populations.45 There are two
intriguing aspects of using claims data for asthma severity
categorization and for predicting outcomes. Although these
methods were developed for use in large populations, Schatz
and Zeiger suggest it should also be applicable to group
practices and individual patient care. Studies using Canadian
administrative databases suggest that this approach can also
be useful outside the US.52,53

Pragmatic research, asthma treatment,
and asthma outcomes
Development of an approach that health care providers can
use to accurately and easily identify patients with persistent
asthma and categorize persistent asthma severity is an essential step towards addressing contentious issues regarding
treatment recommendations in asthma guidelines. Busse has
recently described a number of areas in which there are gaps
in our understanding how to best treat asthma.54 However, it
is clear that for the practicing clinician, the most contentious
issue confronting them in treating asthma is understanding
how combination LABA/ICS therapy affects outcomes in
persistent asthma. The EPR 3 and GINA guidelines recommend use of LABA/ICS combination therapy in patients
with moderate and severe persistent asthma because adding
the LABA will allow use of lower doses of an ICS.6,7 These
recommendations are consistent with findings from a recent
Cochrane review showing that LABA/ICS therapy improves
lung function and reduces symptoms to a significantly greater
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extent than ICS therapy alone.55 Long-term trials have shown
that use of LABA/ICS therapy is associated with a greater
likelihood of patients achieving asthma control than treatment with ICS alone.32
However, there are concerns about the use of LABA/ICS
therapy. Retrospective studies of various insurance claim databases suggest that use of LABA/ICS combination products
often do not conform to guideline recommendations; many
patients treated with a LABA/ICS might have been managed
with an ICS alone.56–58 As discussed above, this treatment
approach might simply reflect the intent of health care providers to provide symptom relief as quickly as possible to
their patients. Unfortunately, the benefits of reducing asthma
impairment with a LABA/ICS might be counterbalanced
by exacerbation risks. The Food and Drug Administration
(FDA) has presented data showing that use of LABA/ICS
might be associated with an increased rate of serious asthma
exacerbations and asthma exacerbations resulting in death
compared to use of ICS alone.59 Concerns about the safety of
LABAs has led the FDA to change the labeling for LABA/
ICS products and to restrict their long-term use. Industry
sponsored reviews of safety databases compiled from
clinical trials involving different LABA/ICS combination
products have not shown evidence of a significant increase
in asthma-related deaths with use of LABA/ICS.60,61 These
analyses, though, might not have had sufficient sample size
to adequately address this risk issue. Independent work has
supported the FDA’s findings of a possible small but finite
increased risk of asthma death with use of a LABA/ICS.62
The recent Cochrane review found that use of an increased
dose of ICS was more effective at preventing exacerbations
than LABA/ICS combination therapy.55
Recent pragmatic research has partly addressed the issue
of outcomes with different asthma treatment approaches.
Price et al compared the effect of choosing a leukotriene
receptor antagonist rather than an ICS as initial therapy and
adding a leukotriene receptor antagonist to an ICS rather
than a LABA as add-on therapy.63 In contrast to guideline
recommendations, patients treated with a leukotriene receptor antagonist had outcomes similar to those treated with an
ICS initially or with a LABA as additional therapy. Important
aspects of the approach used in this study were that patients
were managed by their primary care physician in a real-life
situation, adherence to medication use was considered, clinically relevant outcomes (symptoms and exacerbations) were
measured, variations in drug treatment were allowed (as would
be expected in real-life practice), and the trials lasted long
enough (2 years) to understand effects over time. A limitation
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of this study was its relatively small size, which precluded a
full understanding of safety issues for each treatment option.
However, this type of pragmatic research is a useful model for
larger studies which could be designed to compare increasing
the dose of an ICS against using a lower dose of an ICS with
a LABA. To ensure a large enough sample size to adequately
address the risk component of asthma treatment, these studies could preferentially use administrative databases, either
prospectively or retrospectively. Claims algorithms based
on the modified HEDIS approach could be used to identify
patients with persistent asthma. Asthma severity could also
be approximated with this approach. Patient care would be
determined by the primary care provider without constraints
of a clinical protocol. Symptom control could be inferred
from SABA dispensings. Adherence to use of long-term
controllers could be measured by medication claims. Exacerbations could be defined by oral corticosteroid dispensings,
acute care visits, and hospitalizations. Most important, deaths
could also be tracked.

Diagnosing COPD as the basis
for initiating pharmacotherapy
Similar to asthma, guidelines for COPD also depend
upon categorizing severity as a basis for determining
pharmacotherapy.2,8 However, unlike asthma, COPD guidelines include strict criteria for establishing the diagnosis of
COPD before proceeding with severity categorization. The
clinical presentations of the major COPD subtypes, chronic
bronchitis and emphysema, are well recognized. COPD is
eloquently defined in the Global Initiative for Obstructive
Lung Disease (GOLD) guideline.8 This definition, though, is
not used to diagnose COPD. The GOLD guideline, and others, have an operational definition of COPD, based solely on
a spirometric finding of an FEV1/forced vital capacity (FVC)
ratio below 0.7 following administration of a bronchodilator, which must be met for the diagnosis of COPD to be
confirmed.2,8 There are difficulties, though, with relying on
a single post-bronchodilator spirometry finding to establish
the diagnosis of COPD.

Performing spirometry in the office
An obvious practical problem is that primary care physicians
often do not have access to spirometers in their clinic, do not
train their staff on how to perform spirometry, do not perform
quality control on spirometer performance, and do not understand how to interpret results.64 It is extremely unlikely that
pre- and post-bronchodilator testing as part of spirometry is
being routinely performed in general practice. It should also
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be recognized that not all patients can perform spirometry.
Hardie et al asked 95 participants in a screening study of
elderly asymptomatic non-smokers to perform spirometry.65
Only 71 (75%) could perform this test. The 25% who could not
perform spirometry were more likely to be female and older.
Before interpreting spirometry results, there are a series of
technical issues that the health care provider should consider to
ensure that the test was performed correctly and that the results
were reproducible.66 These issues represent serious obstacles
to widespread use of spirometry for diagnosing COPD.

Interpreting spirometry results
If patients can perform technically acceptable spirometry, the
health care practitioner must then interpret the results. The
current approach to interpreting spirometry results, though,
has limitations. The absolute values for FEV1, FVC, and
FEV1/FVC are not interpreted directly. Instead the actual
values are compared to predicted normal values using regression equations.67 The regression equations for these predicted
values are typically obtained from studying large numbers
of asymptomatic, non-smoking subjects of different ages,
ethnicity, and physical characteristics, such as in the National
Health and Nutrition Examination Survey III (NHANES
III).68 Although predicted values have to be adjusted for
ethnic differences,69,70 the highly selected populations used
for developing reference values would presumably not have
underlying COPD. However, other factors besides smoking
probably contribute to the development of COPD, because
many COPD patients never smoked.71 In a recent international
study, 28% of subjects identified as having COPD by spirometry were never smokers.72 In this study, a history of asthma
and, in women, lower education levels were associated with a
COPD diagnosis. Interestingly, there was a suggestion in this
analysis that lower educational levels in women was actually
a surrogate marker of chronic exposure to biomass fuels used
for cooking and heating, another recognized cause of COPD.
Van Sickle et al also found that socioeconomic factors, such
as high school completion, significantly affected NHANES
III predicted values.73 Wagner suggested that the effect of
socioeconomic status on predicted values may have been
missed in the past because exclusion of smokers might have
preferentially led to fewer subjects in the presumed normal
group with lower socioeconomic status.74 These observations suggest that populations used to develop predicted
normal regression equations might have included patients
with early COPD.
Spirometry results, even when performed under rigorously controlled settings, may be variable. In two long-term
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trials in stable COPD patients, baseline spirometry was
performed on two separate occasions between 3 and 12 weeks
apart and showed substantial variability in FEV1 and FVC
between the two tests.75 Spirometry results may be ambiguous when a reduced FVC, suggesting a restrictive defect, is
found. Currently, little guidance is available on interpreting
a reduced FEV1 in the context of a concomitant reduction
in FVC.76 Spirometry results for 1831 consecutive patients
showed that 470 (25.7%) had a low FVC. 77 Although a
low FVC should indicate a restrictive ventilatory defect,
only a minority of patients with a low FVC were actually
confirmed to have a reduced total lung capacity. Hyatt et al
have described a nonspecific pattern of abnormal spirometry,
characterized by a low FEV1 and FVC with a normal FEV1/
FVC ratio, occurring in 9.5% of routine spirometries.78
In most patients with this nonspecific spirometry pattern
bronchodilators did not change the results. Although this
nonspecific pattern would not meet the GOLD criteria for
COPD, on follow-up over 3 years, 191 (15%) of 1284 patients
were confirmed to have airway obstruction.79 Consequently,
a reduced FVC found on spirometry might represent COPD,
but current strategies for interpreting spirometry results
would not suggest this diagnosis.67

Reversibility testing
There is little information available on predicted normal FEV1,
FVC, and FEV1/FVC values pre- and post-bronchodilator
for the general population. The NHANES III data used
for predicting normal regression equations relied on prebronchodilator spirometry.68 A study from Norway reported
on pre- and post-bronchodilator values for normal subjects
aged between 26 and 82 years, but only 515 participants
were included.80 Given the small overall sample size, it is not
surprising to note that there were only 39 men and 82 women
included in this study over the age of 60, the relevant age for
COPD. As expected, they found that the post-bronchodilator
values were significantly greater than the pre-bronchodilator
values. They also compared the post-bronchodilator FEV1,
FVC, and FEV1/FVC values to pre-bronchodilator values
predicted from standard reference equations and again found
significant differences. The authors speculated that relying on
only the post-bronchodilator FEV1/FVC ratio might reduce
the detection of obstructive airway disease. In earlier work,
this same group showed that this effect did occur.81 In random
screening of adults living in Hordaland County, Norway,
3% of the subjects tested had an FEV1/FVC ratio below
0.70 pre-bronchodilator but above 0.70 post-bronchodilator.
The prevalence of COPD was 27% lower in this screening
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study using the post-bronchodilator FEV1/FVC ratio rather
than the pre-bronchodilator value. Interestingly, 0.5% of
the screened population had a normal FEV 1/FVC ratio
pre-bronchodilator but a low ratio post-bronchodilator. This
effect probably occurred because there may be a more robust
increase in FVC post-bronchodilator than FEV1.82,83 It is often
not appreciated that reversibility can be based on changes in
either FEV1 or FVC.67 Failure to understand how a COPD
patient might respond to a bronchodilator could result in
confusing situations for the general practitioner. A patient
with a low pre-bronchodilator FEV1/FVC but a normal postbronchodilator ratio due to a vigorous FEV1 response would
not be considered to have COPD. Conversely, a patient with
a normal pre-bronchodilator FEV1/FVC ratio but a low postbronchodilator ratio due to a vigorous FVC response would
be diagnosed as having COPD by the GOLD guidelines.
There is uncertainty in how to perform and interpret
reversibility testing.67 One approach is to administer four
puffs of albuterol by metered dose inhaler with a spacer,
but there is no consensus on the type of bronchodilator,
the number of puffs to be administered, and the inhalation
device to be used when performing reversibility testing.
Administering both a SABA and a short-acting inhaled antimuscarinic agent (SAMA) results in a greater bronchodilator
effect than found with a SABA alone.82
Just as there is variability in the FEV1 over time in stable
patients, there is also variability in the FEV1 response to
inhaled bronchodilators in COPD over time. Calverley
et al reported on bronchodilator reversibility in 660 COPD
patients studied on three separate occasions at 4-week
intervals and found that 52.1% of the patients changed
responder status between visits.82 At some visits, patients
were classified as having reversible airway obstruction,
but at other visits the response to bronchodilators was not
as substantial. Han et al observed a similar variability in
bronchodilator responsiveness over time.83 Again, failing to
understand how COPD patients respond to bronchodilators
could result in odd situations which would be difficult for
the general practitioner to interpret. A patient identified as
having COPD because of a minimal bronchodilator effect on
one visit might not have the diagnosis confirmed on another
visit, because of a more robust FEV1 response to inhaled
albuterol. A patient not diagnosed with COPD on one visit
could have COPD diagnosed at a later visit if there were a
vigorous FVC response. An important caveat to the issue of
bronchodilator reversibility, often not recognized in clinical practice, is to ensure that patients do not use either their
regularly scheduled long-acting bronchodilators or as-needed
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short-acting bronchodilators in the hours before spirometry,
as use of these medications will minimize bronchodilator
responsiveness in the laboratory.84

Fixed FEV1/FVC ratio

Using a fixed FEV1/FVC ratio to diagnose COPD fails to
take into account the expected and normal effects of aging
on FEV1 and FVC. With aging both the FEV1 and FVC
decrease, but the FEV1 tends to fall to a greater extent.
Consequently, the FEV1/FVC ratio normally decreases with
age. This physiologic phenomenon can lead to two different
types of diagnostic inaccuracies when relying on the FEV1/
FVC ratio to establish the diagnosis of COPD. A younger
patient with a history consistent with COPD might have an
FEV1/FVC ratio above 0.70 but a ratio well below expected
for their age. This patient might be incorrectly classified as
not having COPD (false negative). Conversely, an older
patient without a history suggesting COPD might have
an FEV1/FVC ratio below 0.70 consistent with their age
predicted value.85 This patient might be falsely identified
as having COPD (false positive). Miller et al found that
false negative findings, ie, missing the diagnosis of COPD,
were more likely to occur in women younger than 45.86
Schermer et al found that false positive findings, ie, overdiagnosis of COPD, occurred more often in middle age and
elderly patients.87 Robberts and Schermer showed that 16%
of 3473 men referred for spirometry by their primary care
physicians would have been incorrectly diagnosed with
COPD if the FEV1/FVC ratio ,0.70 had been the sole criteria (Figure 4).88 Although it is argued that the FEV1/FVC
ratio ,0.70 is a simple and practical operational definition
of COPD,89 a more appropriate physiologic approach would
be to use the lower limit of predicted normal for the FEV1/
FVC ratio.90 Until this issue is resolved, over-diagnosis and
under-diagnosis of COPD will occur.

Pragmatic research approaches
to identifying COPD patients
and categorizing severity
The current operational definition of COPD, which rests solely
on the post-bronchodilator FEV1/FVC ratio, does not seem
either workable or reasonable. There are substantial difficulties
performing and interpreting the results of spirometry. These
difficulties undoubtedly lead to infrequent use of spirometry
by many primary care physicians, which accounts for the
overall under-diagnosis and under-detection of COPD in primary care. Predicted normal reference equations are limited
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Figure 4 The horizontal red line indicates the fixed FEV1/FVC ratio of 0.70. The
black circles above this line represent patients without COPD. The predicted
normal post-bronchodilator FEV1/FVC ratio decreases with age. The black diagonal
line represents the age-adjusted lower limit of normal for the FEV1/FVC for men.
The green circles below this line represent patients with COPD. The red circles
between the two lines indicate the 558 (16% of the entire cohort of 3473 men
studied) symptomatic male current and ex-smokers referred for spirometry testing
who would have been incorrectly diagnosed with COPD based on using the fixed
threshold rather than the predicted lower limit of normal.88
Note: Reproduced from Robberts B, Schermer T. Abandoning FEV1/FVC , 0.70 to detect
airway obstruction. Chest. 2011;139(5):1253–1254 with permission of the publisher.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in one second; FVC, forced vital capacity.

by the population studied and provide little information on the
predicted post-bronchodilator response. Reversibility testing
is not well standardized and is variable over time. Relying on
a strict FEV1/FVC threshold of 0.70 ignores basic physiologic
principles regarding the effect of aging on the lung. Clinical
guidelines recommending treatment approaches based on a
dysfunctional definition of COPD are fundamentally flawed.
Curiously, recent commentaries on controversies in COPD do
not mention this issue, and persist in relying on the GOLD
definition of an FEV1/FVC ratio ,0.70 for COPD.91,92
Pragmatic research is needed to develop a definition of
COPD that is both accurate and readily usable by the primary
care health practitioner. This definition should satisfy two
important points. First, it should not be based on spirometry. Second, it should focus on identifying patients with
more severe COPD. Recognizing the mild COPD patient,
ie, a patient who is either asymptomatic or minimally
symptomatic with an FEV1/FVC ratio ,0.70 but an FEV1
. 80% predicted, may not be helpful. Office spirometry can
significantly improve early detection of COPD,93 but, as the
US Preventive Services Task Force has pointed out, screening
asymptomatic patients for COPD provides no net benefit.94
There is no effective treatment for preventing the accelerated
decline in lung function seen in COPD other than smoking
cessation. All smokers, whether they have COPD or not,
should be advised to stop smoking. Excluding spirometry
as a diagnostic standard and developing a definition oriented
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towards more severe patients should actually make the process of recognizing COPD simpler.
There are useful non-spirometry-based methods for identifying patients with COPD. A recent systematic review provided helpful insights into the diagnostic value of the history
and physical examination for COPD.95 Features in the history,
such as age $45 years, current and heavy smoking, female
sex, complaints of wheeze and dyspnea, and a self-reported
history of COPD, had independent diagnostic value for identifying COPD. Findings on physical examination, like wheeze
and prolonged expiration, also had independent diagnostic
value. Unfortunately, this systematic review included only
a small number of studies and few of the studies reviewed
used the FEV1/FVC ratio ,0.70 as the independent determinant of COPD. Others have found that a patient reported
smoking history of more than 55 pack years, wheezing heard
on auscultation and patient self-reported wheezing almost
assures the presence of airflow obstruction.2 Price et al
developed a symptom-based questionnaire for identifying
COPD in smokers which they validated by comparison to
the standard COPD definition of an FEV1/FVC ratio ,0.70.96
The final questionnaire contained only eight items and could
be easily completed by the patient. Questions were related
to age, smoking history, cough, wheeze, and allergies. The
questionnaire had reasonably good performance characteristics, a specificity of 80.4%, and sensitivity of 72.0% for
identifying COPD.
Approaches to identifying COPD patients using smoking history and symptoms could be improved by incorporating reports of exacerbations, especially those requiring

h ospitalization, ambulatory claims for care related to COPD,
and use of bronchodilators. Recent work has shown that
patients with GOLD Stage 2 COPD (an FEV1 of 50%–79%
predicted) had frequent exacerbations (Figure 5).97 The first
year exacerbation rate in this study for Stage 2 patients was
0.85 per person; 22% had frequent exacerbations and 7% had
been hospitalized for an exacerbation. Gershon et al found
that information available in an administrative database on
hospitalizations and ambulatory care visits attributed to
COPD by a primary care physician was a reasonably accurate
way to identify COPD patients.98 In a large population study
based on administrative data, these authors showed that a
physician diagnosis of COPD based on either an ambulatory care claim or hospitalization was a useful approach in
identifying patients with COPD over time.99 Incorporating
use of medications typically used for managing COPD, such
as inhaled anticholinergic and long-acting bronchodilators,
can be used as part of a non-spirometry-based method for
determining COPD severity.100,101
Future pragmatic research should concentrate on developing a simple, practical, and accurate method for identifying COPD patients who need treatment. Previous work
suggests that a viable approach could be developed based
on three components: a questionnaire regarding smoking
history, exposure to other noxious dusts, and symptoms of
wheeze and cough; findings on physical examination of
wheeze; and an administrative database review of exacerbation history and medication use. A further refinement
of this approach will be to use elements of this method,
such as the number of medications being used, frequency
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Figure 5 As COPD severity stage increases, the frequency of exacerbations requiring hospitalization increases. The percent of patients with frequent exacerbations (ie, two
or more exacerbations per year) also increased with COPD severity stage. In GOLD Stage 2 COPD the exacerbation rates were 0.85 per year. The high exacerbation rate
suggests that an algorithm based on claims for COPD exacerbations could be a useful approach to identifying COPD patients in GOLD Stage 2 and above.96
Note: Reproduced from Price DB, Tinkelman DG, Halbert RJ, et al. Symptom-based questionnaire for identifying COPD in smokers. Respiration. 2006;73(3):285–295 with
permission of the publisher. Copyright New England Journal of Medicine.
Abbreviations: COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Obstructive Lung Disease.
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of exacerbations, use of oxygen, etc, to then categorize
COPD severity.

Pragmatic research, COPD treatment,
and COPD outcomes
With a validated non-spirometric-based method for diagnosing
symptomatic COPD, especially one which can also be used
to categorize COPD severity, difficult questions about how
treatment recommendations in the GOLD guidelines actually
impact outcomes can be addressed with pragmatic research.
An example of a particularly vexing question is whether currently recommended maintenance pharmacotherapy for COPD
in the GOLD guidelines affects survival. For COPD patients
in GOLD Stages 2, 3, and 4 severity, the guidelines recommend regular treatment with some combination of a LABA,
a long-acting inhaled anti-muscarinic agent (LAMA), and a
LABA with an ICS. Each of these products has proven benefits in improving lung function and reducing exacerbations.
However, there are contradictory reports regarding how these
products affect survival. In a 3-year industry sponsored trial,
there was a nonsignificant trend for regular treatment with both
a LABA and a LABA/ICS combination to reduce mortality.102
In a 4-year industry sponsored trial there was a nonsignificant
trend for regular treatment with a LAMA to reduce mortality.103
A pooled safety analysis compiled from the randomized,
double-blind, placebo-controlled clinical trials performed in
COPD with a LAMA during its clinical development also
suggested a trend for improved survival.104 Retrospective
analyses, though, suggested that use of inhaled anti-muscarinic
agents, both short-acting and long-acting, was associated with
an increased risk of cardiovascular deaths.105,106
The FDA has publicly commented that the safety data on
LAMA use from prospective trials was more meaningful than
those from the retrospective analyses.107 Unfortunately, recent
data from prospective trials with a LAMA in a novel inhalation device have also suggested an increased risk of death
with this drug.108,109 Complicating this situation are results
from two other studies comparing outcomes between use of
a LAMA and a combination LABA/ICS product and use of
LAMA and a LABA. In a 2-year, double-blind, randomized,
parallel, industry-sponsored study, patients treated with a
LABA/ICS were significantly less likely to die than those
receiving the LAMA.110 In a retrospective database analysis,
moderate COPD patients initially treated with a LABA had
a lower mortality rate over more than 5 years of follow-up
than those begun on a LAMA.111 These findings suggest that
both LABA and LABA/ICS might provide a survival benefit
in COPD over LAMA. Interestingly, a systematic review
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compared results with LABA/ICS and LABA treatment
and found that combination therapy with LABA/ICS did
not reduce the risk of either death or severe exacerbations
compared to LABA therapy alone.112 Although LABA/ICS
therapy did provide significant improvements in lung function and quality of life compared to LABA treatment, these
benefits were small and probably clinically unimportant. Use
of a LABA/ICS was associated with significantly more side
effects, such as pneumonia, than LABA treatment.
On balance, the results of these studies are concerning.
They suggest serious possible safety concerns with both
LAMA and combination LABA/ICS therapy in COPD.
Surprisingly, monotherapy with a LABA might provide
benefits with fewer risks than either LAMA monotherapy or
combination LABA/ICS treatment. Given the widespread use
of LAMA and LAB A/ICS products in COPD, there is a clear
need to address this issue and pragmatic research is ideally
suited for this purpose. As with asthma, large studies would
be required to address these safety concerns. Prospective
and/or retrospective administrative database analyses would
be appropriate research models. Patients with COPD could
be identified through a claims-based algorithm. Patient care
decisions would be made by the local health care provider.
Severity categorization could be inferred from types of
therapy being used by patients. Multiple outcomes could be
monitored. Exacerbations could be measured by oral corticosteroid and antibiotic dispensings along with acute care visits
and hospitalizations as indicators of exacerbations. Deaths
would be the ultimate outcome of concern.

Conclusion
Asthma and COPD are common diseases which cause
patients and society considerable difficulties. Asthma
patients suffer from limitations in their daily lives due to
uncontrolled symptoms and intermittent exacerbations.
Symptoms and exacerbations in COPD also disrupt daily
life activities. Although asthma is associated with a low
mortality rate, COPD is a deadly disease with an increasing
mortality rate. Both asthma and COPD result in substantial
total direct and indirect health care costs for society. Clinical
practice guidelines provide comprehensive recommendations for the care of asthma and COPD patients. Health care
policy makers have reasonably recognized that improving
outcomes in asthma and COPD should be a priority and
have emphasized consistent use of guideline recommendations to achieve this end. Unfortunately, failure to improve
outcomes may not be because of inconsistent applications
of guideline recommendations, but rather because these
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recommendations might be based on flawed assumptions.
There are difficulties implementing the EPR 3 method for
categorizing asthma severity and the GOLD method for diagnosing COPD. As these serve as the foundation for treatment
recommendations for these diseases, simpler methods, using
readily available information at both the individual practice
and the large population level, should be developed to categorize asthma severity and to diagnose COPD. Once these
methods are developed and validated, pragmatic research will
be of great value in answering important questions about how
guideline-recommended approaches, specifically regarding
use of LABA/ICS in asthma and LAMA and LABA/ICS in
COPD, affect outcomes in real-life situations. Ideally pragmatic research methods developed for use in North America
and Europe could be applied worldwide.
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